Click on image to view larger version.

Figure 1 Screening of patients with VHD or HHD, or healthy controls (Healthy) for anti-beta-AR autoantibodies. (Left) Increased reactivity in ELISA with synthetic peptides corresponding to the aminoterminal (N), second extracellular (ECII), or carboxyterminal (C) domains of human beta-1- (open bars), or beta-2- (closed bars), or both receptor subtypes (hatched bars). (Right) Sera specifically recognizing receptor peptides selected for binding (IFM = indirect fluorescence microscopy, see Fig. 2) and functional interaction (increase in cAMP, see Fig. 3) with intact human beta-AR. Bars represent the number of positive results for each epitope; numbers in parentheses (on top of the bars) indicate cross-reactions with another receptor domain. The total number of autoantibody-positive individuals is given underneath each diagram (brackets).